Ipsen: presents latest data on Iqirvo
(CercleFinance.com) - Late on Friday Ipsen announced that the latest data on Iqirvo (elafibranor 80 mg tablets) - from an interim analysis of a ph.
III trial - will be presented at the American Association for the Study of Liver Disease (AASLD) congress.
Over a three-year period, the Iqirvo data suggest sustained efficacy and corroborate the drug's tolerability profile. In addition [...] patients report to me that they are less affected by itching and fatigue, one of the study's principal investigators, said.
Iqirvo treatment had an impact on pruritus symptoms and surrogate markers of fibrosis. These are major findings for people living with PBC, he added.
The laboratory also points out that no new safety findings were observed.
Data such as these provide prescribers with further strong arguments in favor of Iqirvo, commented Sandra Silvestri, Executive Vice-President and Chief Medical Officer of Ipsen.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
III trial - will be presented at the American Association for the Study of Liver Disease (AASLD) congress.
Over a three-year period, the Iqirvo data suggest sustained efficacy and corroborate the drug's tolerability profile. In addition [...] patients report to me that they are less affected by itching and fatigue, one of the study's principal investigators, said.
Iqirvo treatment had an impact on pruritus symptoms and surrogate markers of fibrosis. These are major findings for people living with PBC, he added.
The laboratory also points out that no new safety findings were observed.
Data such as these provide prescribers with further strong arguments in favor of Iqirvo, commented Sandra Silvestri, Executive Vice-President and Chief Medical Officer of Ipsen.
Copyright (c) 2024 CercleFinance.com. All rights reserved.